Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma.
Larrayoz M, Garcia-Barchino MJ, Celay J, Etxebeste A, Jimenez M, Perez C, Ordoñez R, Cobaleda C, Botta C, Fresquet V, Roa S, Goicoechea I, Maia C, Lasaga M, Chesi M, Bergsagel PL, Larrayoz MJ, Calasanz MJ, Campos-Sanchez E, Martinez-Cano J, Panizo C, Rodriguez-Otero P, Vicent S, Roncador G, Gonzalez P, Takahashi S, Katz SG, Walensky LD, Ruppert SM, Lasater EA, Amann M, Lozano T, Llopiz D, Sarobe P, Lasarte JJ, Planell N, Gomez-Cabrero D, Kudryashova O, Kurilovich A, Revuelta MV, Cerchietti L, Agirre X, San Miguel J, Paiva B, Prosper F, Martinez-Climent JA. Larrayoz M, et al. Among authors: llopiz d. Nat Med. 2023 Mar;29(3):632-645. doi: 10.1038/s41591-022-02178-3. Epub 2023 Mar 16. Nat Med. 2023. PMID: 36928817 Free PMC article.
Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.
Lozano T, Gorraiz M, Lasarte-Cía A, Ruiz M, Rabal O, Oyarzabal J, Hervás-Stubbs S, Llopiz D, Sarobe P, Prieto J, Casares N, Lasarte JJ. Lozano T, et al. Among authors: llopiz d. Oncotarget. 2017 May 13;8(42):71709-71724. doi: 10.18632/oncotarget.17845. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069740 Free PMC article.
When Cancer Vaccines Go Viral.
Repáraz D, Llopiz D, Sarobe P. Repáraz D, et al. Among authors: llopiz d. Clin Cancer Res. 2019 Aug 15;25(16):4871-4873. doi: 10.1158/1078-0432.CCR-19-1652. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227502
Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy.
Navarro F, Casares N, Martín-Otal C, Lasarte-Cía A, Gorraiz M, Sarrión P, Llopiz D, Reparaz D, Varo N, Rodriguez-Madoz JR, Prosper F, Hervás-Stubbs S, Lozano T, Lasarte JJ. Navarro F, et al. Among authors: llopiz d. Oncoimmunology. 2022 May 1;11(1):2070337. doi: 10.1080/2162402X.2022.2070337. eCollection 2022. Oncoimmunology. 2022. PMID: 35529677 Free PMC article.
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P. Llopiz D, et al. Cancer Immunol Immunother. 2019 Mar;68(3):379-393. doi: 10.1007/s00262-018-2283-0. Epub 2018 Dec 13. Cancer Immunol Immunother. 2019. PMID: 30547218 Free PMC article.
34 results